Drug intelligence / Profile preview

ME003

Development stage: Preclinical
Lead developer: Letolab
Modality: Peptides

Overview

ME003 is a peptide-based agonist of the fibroblast growth factor 21 (FGF21) pathway, currently under development by Letolab for the treatment of non-alcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that plays a critical role in regulating glucose and lipid metabolism; its activation is associated with reduced hepatic fat accumulation (steatosis), improved insulin sensitivity, and decreased liver inflammation and fibrosis. ME003 is designed as a therapeutic peptide to mimic or enhance FGF21 signaling to address the underlying metabolic dysregulation in NASH. The program is currently in the IND-enabling phase of development.

Other names: ME003-Letolab-FGF21-peptide-NASHME-003-Letolab-FGF21-peptide-NASHME 003-Letolab-FGF21-peptide-NASH

Targets

FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on ME003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME003.

Explore the full profile